WHO ICTRP trial
Persephone: duration of Herceptin with chemotherapy 6 versus 12 months
ISRCTN52968807 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN52968807 |
|---|---|
| Public title | Persephone: duration of Herceptin with chemotherapy 6 versus 12 months |
| Scientific title | Persephone: duration of Herceptin with chemotherapy 6 versus 12 months |
| Primary sponsor | Cambridge Hospitals NHS Foundation Trust and Cambridge University (UK) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase III |
| Countries | United Kingdom |
| Conditions | HER2-positive early breast cancer Cancer Malignant neoplasm of breast |
| Interventions | Current interventions as of 08/10/2014: Patients will receive during or after a standard regimen of chemotherapy either: 1. The standard treatment, i.e. a dose every 3 weeks for a year (18 doses) or 2. The research treatment, i.e. 9 doses… |
| Registration date | Feb 13, 2007 |
| Target size | 4000 |
| Secondary IDs | 2006-007018-39;NCT00712140;HTA 06/303/98 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: